Background

Mild breathing difficulties are common in children with impaired immunity. If a child develops severe breathing difficulties, this can result in acute respiratory failure (where the lungs no longer function properly). This is characterised by pulmonary oedema, reduced lung compliance and hypoxaemia.

Currently, when a child develops severe breathing difficulties, they will be treated on the ward with oxygen, antibiotics and fluids. If, despite treatment, their breathing difficulties worsen, they will usually be admitted to the intensive care unit for further treatment. This often involves the child receiving a general anaesthetic to allow them to be attached to a mechanical ventilator which helps them breathe.

Overall fatality rates for these children approach 50%.

Continuous positive airways pressure

Continuous positive airways pressure (CPAP) is a technique for keeping the lungs well inflated by the use of gentle air pressure via a face mask or helmet. In theory, holding the lungs open a little more should reduce the effort of breathing, and subsequently reduce the risk of chest infections.

Recent randomised controlled trials of adults with impaired immunity and acute respiratory failure have suggested that using CPAP, before breathing difficulties worsen, reduces the risk of death by around 60%.

Patients in the studies who received CPAP early were less likely to need a general anaesthetic and mechanical ventilation. These studies only involved small numbers of patients who were all adults. More research is therefore needed to understand if CPAP is beneficial to children.

What is SCARF?

A pragmatic, randomised controlled trial in infants and children with severely impaired immunity and acute respiratory failure

Aim

The purpose of this study is to find out if early admission to the intensive care unit for CPAP results in more children recovering from severe breathing difficulties when compared to usual treatment.

Primary objective

Requirement for intubation and invasive mechanical ventilation within 30 days post-randomisation

Site/Patients

- Three paediatric NHS hospitals
- 148 infants and children (74 per arm)

Timeline

![Timeline Chart]

0 hours
- Patient fulfils eligibility

Consented and randomised (as soon as possible)

Up to 24 hours
- Early admission to the paediatric intensive care unit for delivery of continuous positive airways pressure (CPAP) or usual care on ward

Up to 30 days
- Assessments – physiology/intervention – safety

At 30 days
- Survival assessment

At 90 days
- Survival assessment

At 1 year
- Survival assessment
Screening/Eligibility

Infants and children who are receiving treatment on the ward must fulfil the following three inclusion criteria:

- age less than 18 years;
- severely impaired immunity (expected to have impaired immunity for at least three months as a result of a primary diagnosis, therapy or a combination of both);
- acute respiratory failure or acute on chronic respiratory failure.

Consent/Randomisation

As soon as the eligibility criteria are met, consent and randomisation should be completed as soon as possible, with the aim of commencing treatment within 24 hours.

Consent will be sought from the parent/guardian. Assent should be sought from children over 8 years of age (or if deemed appropriate).

Participants will either be randomised to:
- the intervention group – early admission to PICU for CPAP; or
- the control group – stay on the ward to receive usual treatment.

All other care will be at the discretion of the treating clinician.

Funding

Great Ormond Street Hospital Children’s Charity, 10AR31

Sponsor

Great Ormond Street Hospital for Children NHS Foundation Trust

Trial Management

ICNARC Clinical Trials Unit

Team

Chief Investigator
Mark Peters (GOSH, London)

Senior Research Nurse
Amy Jones (GOSH, London)

Research Assistant/Trial Manager
Rahi Jahan (ICNARC, London)

Senior Trial Manager
Paul Mouncey (ICNARC, London)

Trial Statistician
Zohra Zenasni (ICNARC, London)

Senior Statistician
David Harrison (ICNARC, London)

For further information

Rahi Jahan (Research Assistant/Trial Manager) ICNARC
Email scarf@icnarc.org
Tel 020 7269 9277
Fax 020 7831 6879

Napier House
24 High Holborn
London
WC1V 6AZ